- Home
- HHS vs LPCN Comparison
HHS vs LPCN Comparison
Compare HHS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | LPCN |
|---|---|---|
| Founded | 1923 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 19.1M |
| IPO Year | 1994 | 2011 |
Fundamental Metrics
Financial Performance| Metric | HHS | LPCN |
|---|---|---|
| Price | $2.25 | $2.42 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 96.5K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.07 | $1.81 |
| 52 Week High | $4.32 | $12.37 |
Technical Indicators
Market Signals| Indicator | HHS | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 49.56 |
| Support Level | N/A | $2.16 |
| Resistance Level | $2.94 | $2.46 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 39.47 | 48.25 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.